VA 21B7

Drug Profile

VA 21B7

Latest Information Update: 22 Aug 2001

Price : $50

At a glance

  • Originator Laboratorios Vita
  • Class Anxiolytics
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anxiety disorders

Most Recent Events

  • 22 Aug 2001 No-Development-Reported for Anxiety disorders in Spain (Unknown route)
  • 12 Jun 1997 Preclinical development for Anxiety disorders in Spain (Unknown route)
  • 07 Apr 1995 An in vivo study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top